Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exosome Proteomics of SOD1D90A Mutation Suggest Early Disease Mechanisms, and FN1 as a Biomarker.

Annals of clinical and translational neurology - 1 Jan 2026

Gautam Mukesh, Laith Ali, Gunel Aslihan, Yilmaz Melda, Basak Nazli, Idrisoglu Halil, Ozdinler P Hande

Abstract excerpt

Amyotrophic lateral sclerosis (ALS) is a neuromuscular disease. Super oxide dismutase 1 (SOD1) gene mutations cause ALS, and the D90A mutation is associated with primarily upper motor neuron (UMN) loss. OBJECTIVE: Our goal is to reveal the early cellular events in ALS pathology and identify potential pharmacokinetic biomarkers, using well-defined patient populations. METHODS: Exosomes are isolated from serum...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyotrophic Lateral Sclerosis
Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Exosomes

Share to Fibronectins

Share to Mutation

Share to Proteomics

Share to Superoxide Dismutase-1

Source

Open in PubMed Open full text

Identifiers

PMID: 41024384
DOI: 10.1002/acn3.70208
PMCID: PMC12790174

Genes

FN1
SOD1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exosome Proteomics of SOD1D90A Mutation Suggest Early Disease Mechanisms, and FN1 as a Biomarker.PMID 41024384Read ↗

Predicting Phenoconversion to Clinically Manifest ALS: Results of a Large-Scale Proteomic StudySemantic proximity Read ↗

Perspectives in Amyotrophic Lateral Sclerosis: Biomarkers, Omics, and Gene Therapy Informing Disease and TreatmentSemantic proximity Read ↗

Network Analysis of the Cerebrospinal Fluid Proteome Reveals Shared and Unique Differences Between Sporadic and Familial Forms of Amyotrophic Lateral SclerosisSemantic proximity Read ↗

Network analysis of the cerebrospinal fluid proteome reveals shared and unique differences between sporadic and familial forms of amyotrophic lateral sclerosisSemantic proximity Read ↗

A plasma proteomics-based candidate biomarker panel predictive of amyotrophic lateral sclerosisSemantic proximity Read ↗

Muscle proteins in plasma associate to distinguished phenotypes in amyotrophic lateral sclerosisSemantic proximity Read ↗

Redefining ALS: Large-scale proteomic profiling reveals a prolonged pre-diagnostic phase with immune, muscular, metabolic, and brain involvementSemantic proximity Read ↗

Redefining ALS: Large-scale proteomic profiling reveals a prolonged pre-diagnostic phase with immune, muscular, metabolic, and brain involvementSemantic proximity Read ↗

The Need for Biomarkers in the ALS–FTD Spectrum: A Clinical Point of View on the Role of ProteomicsSemantic proximity Read ↗

Blueprint of Collapse: Precision Biomarkers, Molecular Cascades, and the Engineered Decline of Fast-Progressing ALSSemantic proximity Read ↗

Skeletal muscle biomarkers of amyotrophic lateral sclerosis: a large-scale, multi-cohort proteomic studySemantic proximity Read ↗

Analysis of circulating protein aggregates reveals pathological hallmarks of amyotrophic lateral sclerosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.